Ridgeback Biotherapeutics
At Ridgeback Bio, we focus on developing potential medications to treat infectious diseases that have limited available treatment options or none at all, including Ebola and Covid-19. Tens of millions of people worldwide suffer every year from known and emerging infectious diseases that have few therapeutic options, both in the developing world and more recently in global pandemic illness. We commit resources and expertise for undefined and poorly understood disease early in the pharmaceutical development cycle, at a time generally when few stakeholders are prepared to make the necessary commitments.
